Home » CELL GENESYS REPORTS ON TRIAL OF CG0070 -- UPDATE
CELL GENESYS REPORTS ON TRIAL OF CG0070 -- UPDATE
Cell Genesys has announced preliminary results of a Phase I clinical trial of CG0070 in patients with recurrent bladder cancer who have failed previous therapy with bacillus Calmette-Guerin, the current standard therapy for recurrent bladder cancer.
Nine patients have been treated with escalating single-dose administrations of CG0070. Evidence of antitumor activity documented by a complete response at follow-up cystoscopy was obtained in three of the nine patients treated. Treatment was tolerable with no serious adverse events or dose limiting toxicities reported to date.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May